Abliva AB Interim Report January – September 2022
Additional regulatory approvals to start the FALCON study with KL1333 ⎮ World Mitochondrial Disease Week raised awareness of mitochondrial diseases
Press releases
Last day of trading with BTA in Abliva
Abliva AB has carried out a rights issue where the subscription period ended June 27, 2022. The rights issue has been registered with the Swedish Companies Registration Office (Sw. Bolagsverket) and t ...
Abliva publishes prospectus in connection with fully underwritten rights issue and admission to trading of newly issued shares
The Board of Directors in Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) has, in connection with the new issues announced on 31 May, 2022, and the conversion of the Company's convertib ...
Abliva AB Interim Report January – March 2022
First quarter summary
Resolutions from Annual General Meeting in Abliva AB (publ)
Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) today on May 20, 2022 held its Annual General Meeting (“AGM”). A summary of the resolutions follows.
Abliva to issue the Q1 Interim Report by May 31st
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced that The Board of Directo ...
Notice of Annual General Meeting of Abliva AB (publ)
The shareholders of Abliva AB (publ), corporate identity number 556595-6538, are hereby convened to the Annual General Meeting, held at 1 p.m. on Friday, 20 May 2022 at Medicon Village, Scheeletorget ...
Abliva AB Year-End Report January – December 2021
"2021 was a defining year for Abliva, focused on portfolio delivering, de-risking our assets and building relationships as we prepared for success in 2022." - Ellen Donnelly, CEO
Resolution at the Extraordinary General Meeting in Abliva AB (publ)
Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) has today held an Extraordinary General Meeting. A summary of the resolution follows. The resolution was passed unanimously.
Notice of Extraordinary General Meeting of Abliva AB (publ)
The shareholders of Abliva AB (publ), corporate identity number 556595-6538, are hereby convened to the Extraordinary General Meeting (the “EGM”) held at 11.00 a.m. on Friday 14 January 2022 at Medico ...
Abliva AB Interim Report January – September 2021
Endpoint validated enables KL1333 Phase 2/3 study start ⎮ Favorable feedback supports progressing NV354 into Phase 1
Resolutions from Annual General Meeting in Abliva AB (publ)
Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) today on May 20, 2021 held its Annual General Meeting (“AGM”). Due to the continued spread of the coronavirus and the authorities’ regula ...